RU2006115558A - Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы - Google Patents
Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы Download PDFInfo
- Publication number
- RU2006115558A RU2006115558A RU2006115558/04A RU2006115558A RU2006115558A RU 2006115558 A RU2006115558 A RU 2006115558A RU 2006115558/04 A RU2006115558/04 A RU 2006115558/04A RU 2006115558 A RU2006115558 A RU 2006115558A RU 2006115558 A RU2006115558 A RU 2006115558A
- Authority
- RU
- Russia
- Prior art keywords
- ring
- aliphatic group
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
Links
- 0 CCCCC([C@@](C)CCC)[C@@]1*2(CCCC2)C1C Chemical compound CCCCC([C@@](C)CCC)[C@@]1*2(CCCC2)C1C 0.000 description 6
- ZPRZWFMMXITIEN-UHFFFAOYSA-N CC(C(C1)N(C)C(C2)C1C1C2CCCC1)=O Chemical compound CC(C(C1)N(C)C(C2)C1C1C2CCCC1)=O ZPRZWFMMXITIEN-UHFFFAOYSA-N 0.000 description 1
- PSYGDLIDUQPOKY-UHFFFAOYSA-N CC(C(C1)N(C)CC1OCc1cc(cccc2)c2cc1)=O Chemical compound CC(C(C1)N(C)CC1OCc1cc(cccc2)c2cc1)=O PSYGDLIDUQPOKY-UHFFFAOYSA-N 0.000 description 1
- MSALOQXDUIXDDG-UHFFFAOYSA-N CC(C(C1)N(C)CC1OCc1cccc2c1cccc2)=O Chemical compound CC(C(C1)N(C)CC1OCc1cccc2c1cccc2)=O MSALOQXDUIXDDG-UHFFFAOYSA-N 0.000 description 1
- DNCOHZODLHDVGD-UHFFFAOYSA-N CC(C(C1)N(C)CC1OCc1ccccc1)=O Chemical compound CC(C(C1)N(C)CC1OCc1ccccc1)=O DNCOHZODLHDVGD-UHFFFAOYSA-N 0.000 description 1
- CJJIOQWQNCHWOP-MRTLOADZSA-N CC(C(C1)N(C)C[C@@H]1[n](nc1-c2ccccc2)nc1-c1ccccc1)=O Chemical compound CC(C(C1)N(C)C[C@@H]1[n](nc1-c2ccccc2)nc1-c1ccccc1)=O CJJIOQWQNCHWOP-MRTLOADZSA-N 0.000 description 1
- WTYLAGIFKVNSEQ-UHFFFAOYSA-N CC(C(C=CC1CC2NC)N1C2=O)=O Chemical compound CC(C(C=CC1CC2NC)N1C2=O)=O WTYLAGIFKVNSEQ-UHFFFAOYSA-N 0.000 description 1
- PENAODPZFZITCT-UHFFFAOYSA-N CC(C(CC1)N(C2)C1CCC2NC)=O Chemical compound CC(C(CC1)N(C2)C1CCC2NC)=O PENAODPZFZITCT-UHFFFAOYSA-N 0.000 description 1
- PRJWZCFBRYCMOE-UHFFFAOYSA-N CC(C(CC1)N(C2=O)N1CCCN2NC)=O Chemical compound CC(C(CC1)N(C2=O)N1CCCN2NC)=O PRJWZCFBRYCMOE-UHFFFAOYSA-N 0.000 description 1
- VMTLDTWEMMJNCU-UHFFFAOYSA-N CC(C(CC12)N(C)C1NC1C2NCCC1)=O Chemical compound CC(C(CC12)N(C)C1NC1C2NCCC1)=O VMTLDTWEMMJNCU-UHFFFAOYSA-N 0.000 description 1
- UPXMTVUDVIMOMT-UHFFFAOYSA-N CC(C(CC12)N(C)C1Nc1c2cccn1)=O Chemical compound CC(C(CC12)N(C)C1Nc1c2cccn1)=O UPXMTVUDVIMOMT-UHFFFAOYSA-N 0.000 description 1
- MPZORVHGOJJCBE-UHFFFAOYSA-N CC(C(CC12)N(C)C1Nc1c2ccnc1)=O Chemical compound CC(C(CC12)N(C)C1Nc1c2ccnc1)=O MPZORVHGOJJCBE-UHFFFAOYSA-N 0.000 description 1
- APKLCLCQXYADRE-UHFFFAOYSA-N CC(C(CC12)N(C)C1Nc1c2cncc1)=O Chemical compound CC(C(CC12)N(C)C1Nc1c2cncc1)=O APKLCLCQXYADRE-UHFFFAOYSA-N 0.000 description 1
- YPQOSOMZNCTZIV-UHFFFAOYSA-N CC(C(CCC1)N(C2=O)N1CCCN2NC)=O Chemical compound CC(C(CCC1)N(C2=O)N1CCCN2NC)=O YPQOSOMZNCTZIV-UHFFFAOYSA-N 0.000 description 1
- WCWAJWJVMPOYLI-UHFFFAOYSA-N CC(C(CCC1=NC=C2NC)N1C2=O)=O Chemical compound CC(C(CCC1=NC=C2NC)N1C2=O)=O WCWAJWJVMPOYLI-UHFFFAOYSA-N 0.000 description 1
- KVVPVHPVSILHSX-UHFFFAOYSA-N CC(C(CCCC1=NC=C2NC)N1C2=O)=O Chemical compound CC(C(CCCC1=NC=C2NC)N1C2=O)=O KVVPVHPVSILHSX-UHFFFAOYSA-N 0.000 description 1
- PMGQDOGUGBNIHE-UHFFFAOYSA-N CC(C(CNC1CC2NC)N1C2=O)=O Chemical compound CC(C(CNC1CC2NC)N1C2=O)=O PMGQDOGUGBNIHE-UHFFFAOYSA-N 0.000 description 1
- JTZRPWNKLZJZFB-UHFFFAOYSA-N CC(C(COC1CC2NC)N1C2=O)=O Chemical compound CC(C(COC1CC2NC)N1C2=O)=O JTZRPWNKLZJZFB-UHFFFAOYSA-N 0.000 description 1
- AUFZRNJYCVYWAN-UHFFFAOYSA-N CC(C(CSC1CC2NC)N1C2=O)=O Chemical compound CC(C(CSC1CC2NC)N1C2=O)=O AUFZRNJYCVYWAN-UHFFFAOYSA-N 0.000 description 1
- SJEZIHPCSCLGGK-UHFFFAOYSA-N CC(C1N(C)C2NC(CCCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2NC(CCCC3)C3C2C1)=O SJEZIHPCSCLGGK-UHFFFAOYSA-N 0.000 description 1
- WYVCVCNDHCXMPG-UHFFFAOYSA-N CC(C1N(C)C2NC(CCNC3)C3C2C1)=O Chemical compound CC(C1N(C)C2NC(CCNC3)C3C2C1)=O WYVCVCNDHCXMPG-UHFFFAOYSA-N 0.000 description 1
- LERQTEOOMKVSKM-UHFFFAOYSA-N CC(C1N(C)C2NC(CNCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2NC(CNCC3)C3C2C1)=O LERQTEOOMKVSKM-UHFFFAOYSA-N 0.000 description 1
- GZBPEQHESSJRPW-UHFFFAOYSA-N CC(C1N(C)C2NC3NCCCC3C2C1)=O Chemical compound CC(C1N(C)C2NC3NCCCC3C2C1)=O GZBPEQHESSJRPW-UHFFFAOYSA-N 0.000 description 1
- LEWRGDPKNRUOBT-UHFFFAOYSA-N CC(C1N(C)C2Nc3cccnc3C2C1)=O Chemical compound CC(C1N(C)C2Nc3cccnc3C2C1)=O LEWRGDPKNRUOBT-UHFFFAOYSA-N 0.000 description 1
- BVVCPCIUYCENAS-UHFFFAOYSA-N CC(C1N(C)C2OC(CCCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2OC(CCCC3)C3C2C1)=O BVVCPCIUYCENAS-UHFFFAOYSA-N 0.000 description 1
- FDIKJQSLNVXCGP-UHFFFAOYSA-N CC(C1N(C)C2SC(CCCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2SC(CCCC3)C3C2C1)=O FDIKJQSLNVXCGP-UHFFFAOYSA-N 0.000 description 1
- UGXICRZJJBNLES-UHFFFAOYSA-N CC(C1N(C)CC2C1C1CC2CC1)=O Chemical compound CC(C1N(C)CC2C1C1CC2CC1)=O UGXICRZJJBNLES-UHFFFAOYSA-N 0.000 description 1
- AZZDJWMTNMLXTE-UHFFFAOYSA-N CC(C1N(C)CC2C1C1NC2CC1)=O Chemical compound CC(C1N(C)CC2C1C1NC2CC1)=O AZZDJWMTNMLXTE-UHFFFAOYSA-N 0.000 description 1
- DTXRKOMFJJIHQQ-UHFFFAOYSA-N CC(C1N(C)CC2C1C1SC2CC1)=O Chemical compound CC(C1N(C)CC2C1C1SC2CC1)=O DTXRKOMFJJIHQQ-UHFFFAOYSA-N 0.000 description 1
- MBYLCPNYNFPEGO-UHFFFAOYSA-N CC(C1N(C)CC2C1SCCC2)=O Chemical compound CC(C1N(C)CC2C1SCCC2)=O MBYLCPNYNFPEGO-UHFFFAOYSA-N 0.000 description 1
- OEKQXFLIHRRQRX-UHFFFAOYSA-N CC(C1N(C)Cc2c(cc3)[o]c3c12)=O Chemical compound CC(C1N(C)Cc2c(cc3)[o]c3c12)=O OEKQXFLIHRRQRX-UHFFFAOYSA-N 0.000 description 1
- NWTVYVJSHUOOCE-UHFFFAOYSA-N CC(C1N(CC(CC2)NC)C2NC1)=O Chemical compound CC(C1N(CC(CC2)NC)C2NC1)=O NWTVYVJSHUOOCE-UHFFFAOYSA-N 0.000 description 1
- APHUYPADINESLM-UHFFFAOYSA-N CC(C1N(CC(CC2)NC)C2OC1)=O Chemical compound CC(C1N(CC(CC2)NC)C2OC1)=O APHUYPADINESLM-UHFFFAOYSA-N 0.000 description 1
- ULSXBYJFOPUNQS-UHFFFAOYSA-N CC(C1N(CC(CC2)NC)C2SC1)=O Chemical compound CC(C1N(CC(CC2)NC)C2SC1)=O ULSXBYJFOPUNQS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51015603P | 2003-10-10 | 2003-10-10 | |
US60/510,156 | 2003-10-10 | ||
US51376803P | 2003-10-23 | 2003-10-23 | |
US60/513,768 | 2003-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2006115558A true RU2006115558A (ru) | 2007-11-20 |
Family
ID=34467967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006115558/04A RU2006115558A (ru) | 2003-10-10 | 2004-10-08 | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы |
Country Status (14)
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU227742B1 (en) * | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
AU2001251165A1 (en) * | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
WO2004092161A1 (en) * | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
PE20050251A1 (es) | 2003-07-18 | 2005-04-13 | Vertex Pharma | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc |
AR045596A1 (es) * | 2003-09-05 | 2005-11-02 | Vertex Pharma | Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc |
JP4685775B2 (ja) | 2003-09-18 | 2011-05-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、とりわけhcvns3−ns4aプロテアーゼの阻害剤 |
CA2541634A1 (en) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
ZA200603863B (en) * | 2003-10-27 | 2007-11-28 | Vertex Pharma | Combination for HCV treatment |
US7683033B2 (en) * | 2004-02-04 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EA019888B1 (ru) | 2005-07-25 | 2014-07-30 | Интермьюн, Инк. | Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза |
EP2256113A1 (en) * | 2005-08-02 | 2010-12-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
DK1999129T3 (da) | 2005-10-11 | 2011-02-07 | Intermune Inc | Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
EP1993994A2 (en) | 2006-03-16 | 2008-11-26 | Vertex Pharmceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
RU2448976C2 (ru) * | 2006-04-11 | 2012-04-27 | Новартис Аг | Ингибиторы hcv/вич и их применение |
KR101069051B1 (ko) | 2006-05-23 | 2011-09-29 | 아이알엠 엘엘씨 | 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물 |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2117537A1 (en) | 2007-02-09 | 2009-11-18 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
MX2009009176A (es) * | 2007-02-27 | 2009-09-28 | Vertex Pharma | Inhibidores de serina-proteasas. |
GEP20125645B (en) | 2007-02-27 | 2012-09-25 | Vertex Pharma | Co-crystals and pharmaceutical compositions comprising the same |
BRPI0811020A2 (pt) * | 2007-05-03 | 2015-07-21 | Intermune Inc | Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral. |
CA2686546A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
JP5443360B2 (ja) | 2007-08-30 | 2014-03-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | 共結晶体およびそれを含む医薬組成物 |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
JP5755450B2 (ja) | 2007-12-21 | 2015-07-29 | セルジーン アビロミクス リサーチ, インコーポレイテッド | Hcvプロテアーゼ阻害剤およびその使用 |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
JP5755449B2 (ja) | 2007-12-21 | 2015-07-29 | セルジーン アビロミクス リサーチ, インコーポレイテッド | Hcvプロテアーゼ阻害剤およびその使用 |
EP2252311A1 (en) * | 2008-01-24 | 2010-11-24 | Enanta Pharmaceuticals, Inc. | Heteroaryl-containing tripeptide hcv serine protease inhibitors |
JP5574982B2 (ja) * | 2008-02-04 | 2014-08-20 | イデニク プハルマセウティカルス,インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
AP2010005416A0 (en) * | 2008-04-15 | 2010-10-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication. |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009148923A1 (en) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CA2729168A1 (en) | 2008-07-02 | 2010-02-04 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AP2011005695A0 (en) * | 2008-10-15 | 2011-06-30 | Intermune Inc | Therapeutic antiviral poptides. |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8315815B2 (en) | 2008-12-30 | 2012-11-20 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
US8073632B2 (en) * | 2008-12-30 | 2011-12-06 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
US8321151B2 (en) | 2008-12-30 | 2012-11-27 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
US8193372B2 (en) | 2009-03-04 | 2012-06-05 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole HCV polymerase inhibitors |
CA2758072A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8512690B2 (en) * | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
JP2013501068A (ja) | 2009-08-05 | 2013-01-10 | アイディニックス ファーマシューティカルズ インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
EP2483290A4 (en) * | 2009-09-28 | 2013-05-01 | Intermune Inc | CYCLIC PEPTIC INHIBITORS FOR REPLICATION OF HEPATITIS C VIRUS |
WO2011041551A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
JP2013514982A (ja) | 2009-12-18 | 2013-05-02 | イデニク プハルマセウティカルス,インコーポレイテッド | 5,5−縮合アリーレン又はヘテロアリーレンc型肝炎ウイルス阻害剤 |
AR094621A1 (es) | 2010-04-01 | 2015-08-19 | Idenix Pharmaceuticals Inc | Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2755985B1 (en) | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Compounds and pharmaceutical compositions for the treatment of viral infections |
EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
AU2012345732B2 (en) | 2011-11-30 | 2016-07-14 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
AU2013266393B2 (en) | 2012-05-22 | 2017-09-28 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
US10513534B2 (en) | 2012-10-08 | 2019-12-24 | Idenix Pharmaceuticals Llc | 2′-chloro nucleoside analogs for HCV infection |
WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
SG11201502802PA (en) | 2012-10-19 | 2015-05-28 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014078436A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
US20140140951A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Rp-Nucleoside Analog |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
EP3063165A1 (en) | 2013-11-01 | 2016-09-07 | Idenix Pharmaceuticals LLC | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
US10683321B2 (en) | 2013-12-18 | 2020-06-16 | Idenix Pharmaceuticals Llc | 4′-or nucleosides for the treatment of HCV |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
WO2015134780A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
AU2016216782C1 (en) * | 2015-02-13 | 2021-02-18 | Oxford Drug Design Limited | Novel N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors |
CR20180413A (es) | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | Inhibidores de la proteína quinasa 1 que interactua con el receptor |
GB201617064D0 (en) | 2016-10-07 | 2016-11-23 | Inhibox Limited And Latvian Institute Of Organic Synthesis The | Compounds and their therapeutic use |
EP3552017B1 (en) | 2016-12-09 | 2022-02-23 | Denali Therapeutics Inc. | Compounds useful as ripk1 inhibitors |
EP3891508A1 (en) | 2018-12-04 | 2021-10-13 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0727419B1 (en) | 1992-12-29 | 2002-02-27 | Abbott Laboratories | Intermediates for the preparation of retroviral protease inhibiting compounds |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
RU95104898A (ru) * | 1994-03-31 | 1996-12-27 | Бристоль-Мейерз Сквибб Компани (US) | Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
IL126674A (en) | 1996-04-23 | 2005-08-31 | Vertex Pharma | Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives |
JPH11513890A (ja) | 1996-05-10 | 1999-11-30 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼの合成インヒビター |
HU227742B1 (en) * | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
JP4327910B2 (ja) | 1997-03-14 | 2009-09-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | Impdh酵素のインヒビター |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
JP4452401B2 (ja) | 1997-08-11 | 2010-04-21 | ベーリンガー インゲルハイム (カナダ) リミテッド | C型肝炎ウイルス阻害ペプチドアナログ |
DK1003775T3 (da) | 1997-08-11 | 2005-05-30 | Boehringer Ingelheim Ca Ltd | Hepatitis C-inhibitorpeptider |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
DE69934104T2 (de) | 1998-03-31 | 2007-06-28 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren von serinproteasen, insbesondere von hepatitis c virus ns3 protease |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
DE19836514A1 (de) | 1998-08-12 | 2000-02-17 | Univ Stuttgart | Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette |
GB9825946D0 (en) | 1998-11-26 | 1999-01-20 | Angeletti P Ist Richerche Bio | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
JP4184610B2 (ja) | 1999-03-19 | 2008-11-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Impdh酵素のインヒビター |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
CA2376961A1 (en) | 1999-07-26 | 2001-02-01 | Bristol-Myers Squibb Pharma Company | Lactam inhibitors of hepatitis c virus ns3 protease |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
WO2001064678A2 (en) | 2000-02-29 | 2001-09-07 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
AU2001251165A1 (en) | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
ES2317900T3 (es) | 2000-04-05 | 2009-05-01 | Schering Corporation | Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2. |
CN1432022A (zh) | 2000-04-19 | 2003-07-23 | 先灵公司 | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 |
HUP0303358A3 (en) | 2000-07-21 | 2005-10-28 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them |
AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
KR100904788B1 (ko) * | 2000-07-21 | 2009-06-25 | 쉐링 코포레이션 | C형 간염 바이러스의 ns3-세린 프로테아제억제제로서의 신규한 펩티드 |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
AU2002248147B2 (en) | 2000-11-20 | 2006-04-06 | Bristol-Myers Squibb Company | Hepatitis C tripeptide inhibitors |
AU2002230764A1 (en) | 2000-12-13 | 2002-06-24 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
DE60217114T2 (de) | 2001-07-11 | 2007-10-25 | Vertex Pharmaceuticals Inc., Cambridge | Verbrückte bizyklische serinproteaseinhibitoren |
JP4460294B2 (ja) * | 2001-10-24 | 2010-05-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | 縮合環系を組み込んだ、セリンプロテアーゼ、特にc型肝炎ウイルスns3−ns4aプロテアーゼの阻害剤 |
CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
EP2468744A2 (en) * | 2002-04-11 | 2012-06-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
CA2515216A1 (en) | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
DE10315645B4 (de) | 2003-04-04 | 2005-07-14 | Zf Boge Elastmetall Gmbh | Hydraulisch dämpfendes Gummibuchsenlager für vertikale Montage |
JP2006526011A (ja) * | 2003-04-11 | 2006-11-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ(特に、hcvns3−ns4aプロテアーゼ)のインヒビター |
WO2004092161A1 (en) * | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
AU2004233757B2 (en) | 2003-05-01 | 2007-08-02 | The Procter & Gamble Company | Striped liquid personal cleansing compositions containing a cleansing phase and a separate benefit phase comprising a water in oil emulsion |
JP4447603B2 (ja) * | 2003-05-21 | 2010-04-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビター化合物 |
PE20050251A1 (es) * | 2003-07-18 | 2005-04-13 | Vertex Pharma | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc |
AR045596A1 (es) | 2003-09-05 | 2005-11-02 | Vertex Pharma | Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc |
JP4685775B2 (ja) | 2003-09-18 | 2011-05-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、とりわけhcvns3−ns4aプロテアーゼの阻害剤 |
CA2541634A1 (en) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
US7683033B2 (en) | 2004-02-04 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
-
2004
- 2004-10-08 CA CA002541634A patent/CA2541634A1/en not_active Abandoned
- 2004-10-08 TW TW093130680A patent/TW200528472A/zh unknown
- 2004-10-08 MX MXPA06004006A patent/MXPA06004006A/es active IP Right Grant
- 2004-10-08 NZ NZ546663A patent/NZ546663A/en not_active IP Right Cessation
- 2004-10-08 CN CN201010183514A patent/CN101857631A/zh active Pending
- 2004-10-08 EP EP04794554.8A patent/EP1692157B1/en active Active
- 2004-10-08 JP JP2006534377A patent/JP2007532474A/ja active Pending
- 2004-10-08 EP EP10183579A patent/EP2361925A1/en not_active Withdrawn
- 2004-10-08 KR KR1020117029638A patent/KR20120010278A/ko not_active Application Discontinuation
- 2004-10-08 RU RU2006115558/04A patent/RU2006115558A/ru not_active Application Discontinuation
- 2004-10-08 KR KR1020067006901A patent/KR20060130027A/ko not_active Application Discontinuation
- 2004-10-08 AU AU2004282148A patent/AU2004282148A1/en not_active Abandoned
- 2004-10-08 WO PCT/US2004/033238 patent/WO2005037860A2/en active Application Filing
- 2004-10-12 US US10/964,214 patent/US7208600B2/en not_active Expired - Fee Related
-
2006
- 2006-04-09 IL IL174863A patent/IL174863A0/en unknown
- 2006-05-10 NO NO20062101A patent/NO20062101L/no unknown
-
2007
- 2007-03-09 US US11/716,248 patent/US8039623B2/en not_active Expired - Fee Related
-
2011
- 2011-08-18 JP JP2011179106A patent/JP2011246487A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ546663A (en) | 2010-01-29 |
MXPA06004006A (es) | 2006-06-28 |
JP2007532474A (ja) | 2007-11-15 |
CA2541634A1 (en) | 2005-04-28 |
US20050137140A1 (en) | 2005-06-23 |
TW200528472A (en) | 2005-09-01 |
US8039623B2 (en) | 2011-10-18 |
NO20062101L (no) | 2006-07-05 |
KR20120010278A (ko) | 2012-02-02 |
KR20060130027A (ko) | 2006-12-18 |
US7208600B2 (en) | 2007-04-24 |
WO2005037860A2 (en) | 2005-04-28 |
EP1692157B1 (en) | 2013-04-17 |
IL174863A0 (en) | 2008-02-09 |
EP1692157A2 (en) | 2006-08-23 |
CN101857631A (zh) | 2010-10-13 |
US20070161789A1 (en) | 2007-07-12 |
AU2004282148A1 (en) | 2005-04-28 |
JP2011246487A (ja) | 2011-12-08 |
EP2361925A1 (en) | 2011-08-31 |
WO2005037860A3 (en) | 2005-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006115558A (ru) | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы | |
RU2006105002A (ru) | Ингибиторы сериновых протеаз, в частности, нс-3-нс4а протеазы | |
RU2006110934A (ru) | 2-амидо-4-арилокси-1-карбонилпирролидиновые производные в качестве ингибиторов серинпротеаз, в частности, протеазы ns3-ns4a hcv | |
JP2007532474A5 (US08039623-20111018-C00042.png) | ||
RU2004133044A (ru) | Ингибиторы сериновых протеаз, в частности, протеазы ns3-ns4a hcv | |
RU2008108024A (ru) | Ингибиторы серинпротеазы | |
JP2005535574A5 (US08039623-20111018-C00042.png) | ||
WO2005035525B1 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
CN100402549C (zh) | 桥连二环的丝氨酸蛋白酶抑制剂 | |
RU2010135497A (ru) | Ингибирование протеазы ns3-ns4 вируса hcv | |
JP4806154B2 (ja) | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼのインヒビター | |
ES2381548T3 (es) | Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A | |
AU721079B2 (en) | Peptidyl heterocycles useful in the treatment of thrombin related disorders | |
EP1730167B1 (en) | Macrocyclic peptides active against the hepatitis c virus | |
JP5049788B2 (ja) | ウイルス感染症を処置するためのアンドログラフォライド(andrographolide)誘導体 | |
JP2007504251A5 (US08039623-20111018-C00042.png) | ||
AR045769A1 (es) | Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c) | |
MX2011006239A (es) | Analogos ciclicos de peptido de 4-amino-4-oxobutanoilo, inhibidores de replica viral. | |
KR20000049263A (ko) | 세린 프로테아제, 특히 c형 간염 바이러스 ns3 프로테아제의억제제 | |
JP2009506078A5 (US08039623-20111018-C00042.png) | ||
JP2006505618A (ja) | Hcvセリンプロテアーゼの有効な阻害剤 | |
EA007739B1 (ru) | Гетероциклические трипептиды в качестве ингибиторов вируса гепатита с | |
WO2005077969A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
EA022118B1 (ru) | Ингибиторы протеазы hcv | |
CA2747636A1 (en) | Hcv ns3 protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20071211 |